Embecta (Nasdaq:EMBC) announced a new publication introducing best practices for insulin injection techniques and education. The publication in the Mayo Clinic Proceedings introduces the FITTER Forward Expert Recommendations. These best practices, authored by a panel of 16 diabetes specialists from 13 countries, highlight the critical need for improved training and standardization in insulin delivery. It […]
Diabetes
Glucotrack expects FDA IDE for implantable CBGM this year
Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption (IDE) for its long-term CBGM later this year. Rutherford, New Jersey-based Glucotrack develops a long-term implantable continuous blood glucose monitor (CBGM). The device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, […]
SiBionics unveils ‘world’s thinnest’ CGM, earns CE mark
SiBionics announced today that it unveiled its GS3 continuous glucose monitor (CGM), which now has CE mark approval. The company unveiled the device — which it touts as the world’s thinnest CGM — at last week’s 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam. GS3 features an ultra-compact design and […]
Dexcom picks longtime Masimo exec as next CCO
Dexcom (Nasdaq:DXCM) announced today that it appointed Jon Coleman as its new chief commercial officer (CCO). Coleman assumes responsibility for Dexcom’s global commercial organization, including global sales, marketing and customer experience. He takes over for Teri Lawver, who in October announced her plans to retire as CCO of the continuous glucose monitor (CGM) maker. At […]
Beta Bionics posts Q4 sales beat to cap off ‘momentum-building year’
Beta Bionics (Nasdaq:BBNX) shares rose after hours today on fourth-quarter results that topped the consensus sales forecast. Shares of BBNX ticked up nearly 2% to $15.50 apiece in poost-market trading today. This is the company’s first quarterly earnings report after it went public through a $234.6 million IPO in January. The Irvine, California-based automated insulin […]
Nanowear enters CGM licensing, data partnership with Dexcom
Nanowear announced today that it entered into a partnership with Dexcom to ingest glucose data from its latest continuous glucose monitors (CGMs). The partnership will see Nanowear’s SimpleSense nanotechnology-enabled wearable, mobile and software diagnostics platform take data from the Dexcom G7 CGM, combining continuous glucose readings, blood pressure, ECGs, lung volume, respiration and hemodynamics. This […]
Glooko integrates diabetes management platform with Abbott FreeStyle Libre
Glooko announced today that its platform now supports the Abbott FreeStyle Libre continuous glucose monitoring (CGM) in the U.S. The integration further strengthens Glooko’s commitment to offering a comprehensive, all-in-one solution for managing diabetes. Palo Alto, California-based Glooko’s current platforms enable patients to share diabetes data with healthcare providers. That includes blood glucose readings, insulin […]
The biggest diabetes tech news out of ATTD 2025
Last week, Amsterdam played host to this year’s edition of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). For the 18th edition of this event, some of the biggest names in diabetes technology put their latest innovations on display. Updates for insulin delivery and glucose monitoring technologies dominated the headlines as many […]
Beta Bionics founder talks bringing ‘bionic pancreas’ to market
Around 25 years ago, Ed Damiano’s 11-month-old son developed type 1 diabetes. Damiano, a professor of mechanical engineering, made it his goal to make it easier to manage his young son’s condition. Speaking on a panel at the MassMedic 2025 MedTech Symposium in Boston earlier this month, Damiano said: “I started to think about ways […]
Why Dexcom is making a push to bring CGM to more people with type 2 diabetes
Of the hundreds of millions of people living with diabetes, the vast majority live with type 2. Dexcom (Nasdaq:DXCM) wants to make sure they have the tools to manage that. The International Diabetes Federation says that more than 90% of people with diabetes have type 2 diabetes. Yet, that population remains significantly under-penetrated by the […]
